News & Press Releases

[October 19, 2016]

Newly Published Data in the Archives of Dermatological Research Reveal That Hyperhidrosis is More Prevalent, Severe and Socially Debilitating than Previously Reported.

[March 7, 2016]

Brickell's Phase 2b Study Results for BBI-4000 Presented at the Late-breaking Research Forum during the 74th American Academy of Dermatology Annual Meeting.

[December 17, 2015]

Brickell Achieves Statistically Significant and Clinically Meaningful Phase 2b Results for BBI-4000 (Sofpironium Bromide) in Patients with Hyperhidrosis.

[November 24, 2015]

Brickell Secures Exclusive WW Rights to Novel Series of RORγ Inhibitors as Potential Topical Therapy for Psoriasis.

[July 8, 2015]

Brickell Announces Appointment of Industry Veteran Dr. Patricia Walker, MD, PhD as President and Chief Scientific Officer.

[April 1, 2015]

Brickell Signs Exclusive License and Development Agreement for its novel, topical soft-anticholigenric, BBI-4000, with Kaken Pharmaceutical Co., Ltd. in Japan.

[February 3, 2015]

Brickell Announces $10M Series C Financing, Initiates Phase 2b Study of BBI-4000 in Patients with Axillary Hyperhidrosis and Acquires Novel, Clinical-Stage Compound for the Oral Treatment of Atopic Dermatitis. 

[September 24, 2014]

Brickell Announces Positive Preliminary Results of a Pilot Clinical Study of BBI-4000 for the Treatment of Hyperhidrosis and welcomes Charlie Stiefel and Bill Ju to Board of Directors.

[June 30, 2014]

Brickell announces licensing agreement for its novel retinoid therapy, BBI-3000, with Merz North America.

[February 26, 2013]

Brickell announces $7M Series B financing; AMOREPACIFIC Group, the largest cosmetic and aesthetics company in Korea, leads financing and becomes strategic partner.

[December 2012]

Brickell enters into a license agreement with Bodor Laboratories, Inc. for exclusive rights to BBI-4000, a novel, topical soft anticholinergic for the treatment of hyperhidrosis (excessive sweating).

[June 2012]

Brickell enters into a license agreement for exclusive rights to BBI-3000, a novel, potent topical/oral retinoid, acting as a highly selective RXR agonist, for the treatment of skin conditions responsive to retinoid therapy.

[April 2011]

Brickell enters into a license agreement with the University of Manchester , Inc. for exclusive rights to BBI-2111 (now BBI-2000), a novel compound with anti-inflammatory properties, for the treatment of dermatological indications.